FSCN1 and in situ carcinoma: The immunoexpression of fascin was significantly higher in dysplasia and in situ carcinoma than in benign diseases [29], reinforcing our findings that fascin can be helpful for improving the diagnostic accuracy of dysplasias that will progress to oral carcinoma.